(From AFX UK (Focus))
LONDON (AFX) - Stem Cell Sciences PLC said its Neural Stem Cells (NS cells) are to enter pre-clinical testing for spinal cord injury in a collaboration with Regenerative Medicine Institute (REMEDI) at the National University of Ireland, Galway.
The initial study, whose results are expected in the first quarter of 2007, will examine the ability of the NS cells to provide functional improvements in models of spinal cord injury at REMEDI, the biotechnology company said in a statement.
Spinal cord injury affects more than 25 million people worldwide, with 130,000 new cases reported each year. Embargoed until 07.00
2 November 2006
Stem Cell Sciences plc
("Stem Cell Sciences", "SCS" or "the Group") Stem Cell Sciences' NS Cells to begin Preclinical Trials for Spinal Cord Injury Stem Cell Sciences plc (AIM:STEM), the global biotechnology company focused on the commercialisation of stem cells and stem cell technologies in research and novel cell-based therapies, is …